Please ensure Javascript is enabled for purposes of website accessibility

SciClone Q4 Net Drops Steeply

By Eric Volkman - Apr 1, 2013 at 8:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical company's bottom line drops by nearly $10 million.

SciClone (SCLN) results for the company's Q4 and 2012 have been released, following a delay due to restatement. For the quarter, net revenues were $33 million, down from the nearly $40 million in the same period the previous year. Non-GAAP net profit dropped more precipitously, to $2.0 million ($0.04 per diluted share) from Q4 2011's bottom line of $11.4 million ($0.19). 

For fiscal 2012, net revenues were higher on a year-over-year basis. They totaled $156 million compared to the 2011 figure of $133 million. Net profit inched up to $36.7 million ($0.63 per diluted share) for the year against 2011's $34.0 million ($0.59).

SciClone also provided forward guidance. For full-year 2013, revenues are expected to come in at $150 million to $155 million and EPS should be $0.66 to $0.72.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

SciClone Pharmaceuticals, Inc. Stock Quote
SciClone Pharmaceuticals, Inc.
SCLN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.